George Papaliodis

Board-certified in internal medicine and ophthalmology, Dr. George Papaliodis specializes in the treatment of systemic diseases that are associated with ocular inflammation. As the director of the Ocular Immunology and Uveitis Service, he treats patients with a range of ocular inflammatory disorders at Mass. Eye and Ear's main Charles Street campus and Stoneham satellite office, as well at Massachusetts General Hospital. In addition, as a member of the Comprehensive Ophthalmology and Cataract Consultation Service, he performs cataract surgery at Mass. Eye and Ear's Charles Street location.

While most of his time is devoted to patient care, Dr. Papaliodis has been involved in a number of research projects, including an investigation of LX-211 for the treatment of inflammatory eye diseases and a study of pulsed electromagnetic field therapy for the treatment of uveitis. He also investigated serum biomarkers in ocular sarcoidosis and was part of the Abbvie sponsored study evaluating Humira for the treatment of uveitis.

A renowned expert in ocular inflammatory diseases, Dr. Papaliodis has presented at many national and international conferences, including those hosted by the International Ocular Inflammation Society, the American College of Rheumatology, the Aegean Retina Society, the New England Ophthalmologic Society, the North Carolina Dermatology Society, the Dominican Republic National Ophthalmologic Society, the Association for Research in Vision and Ophthalmology, and SECO International.

In addition to establishing one of the largest ocular inflammatory disease practices in the country, he has played a critical role outlining the teaching curriculum in the field of uveitis/ocular inflammation for the residents at Harvard Medical School.

Research

Dr. Papaliodis' research has focused on attempting to identify disease mechanisms that can induce uveitis and novel treatments for intraocular inflammation. He has studied serum biomarkers and genetics in ocular sarcoidosis along with the role of vitamin D in ocular inflammatory disorders. He has been an investigator in multiple drug-company sponsored clinical trials to establish the efficacy of therapeutic agents for uveitis. In collaboration with Dr. John Kempen, he is currently assessing factors that may influence the development of ocular complications in those who have intraocular inflammation.

Education

1992: BS, Chemistry, Physics, and Biology, summa cum laude, Texas Christian University

1995: MD, University of Texas Southwestern Medical School

Postgraduate Training

1996: Internship, Internal Medicine, Massachusetts General Hospital

1999: Residency, Ophthalmology, University of Texas Southwestern

2001: Residency, Internal Medicine, Massachusetts General Hospital

2002: Fellowship, Ocular Immunology and Uveitis, Massachusetts Eye and Ear

Academic Appointments

2018-present: Associate Professor of Ophthalmology, Harvard Medical School

2011-2018: Assistant Professor of Ophthalmology, Harvard Medical School

2005-2011: Instructor in Ophthalmology, Harvard Medical School

2003-2005: Instructor in Medicine, Harvard Medical School

2002-2003: Instructor in Ophthalmology, Harvard Medical School

Professional Memberships

American Uveitis Society

Honors

Massachusetts Eye and Ear Resident Teaching Award

Publications

Publications powered by Harvard Catalyst Profiles Restoration of Vision in Severe, Cicatricial, Ocular Surface Disease With the Boston Keratoprosthesis Type II. Am J Ophthalmol. 2022 Jul 16; 243:42-54.

Anti-infliximab antibodies and clinical response in noninfectious uveitis and scleritis patients treated with infliximab: A retrospective review. Am J Ophthalmol Case Rep. 2022 Sep; 27:101634.

Primary central nervous system lymphoma: Inter-compartmental progression. EJHaem. 2022 May; 3(2):362-370.

Uveitis Specialists Harnessing Disruptive Technology during the COVID-19 Pandemic and Beyond. Semin Ophthalmol. 2021 May 19; 36(4):296-303.

Comparison of Modified Posterior Sub-Tenon's vs. Trans-Septal Triamcinolone Injection for Non-infectious Uveitis. Ocul Immunol Inflamm. 2021 Jul 04; 29(5):857-864.

Real-Time Multiplex PCR Analysis in Infectious Uveitis. Semin Ophthalmol. 2019; 34(4):252-255.

Ocular Adverse Events following Use of Immune Checkpoint Inhibitors for Metastatic Malignancies. Ocul Immunol Inflamm. 2020 Aug 17; 28(6):854-859.

Association of Low Vitamin D Levels with Noninfectious Uveitis and Scleritis. Ocul Immunol Inflamm. 2019; 27(4):602-609.

A 70-Year-Old Man With Pain and a Creamy Elevated Lesion After Transscleral Cyclophotocoagulation. JAMA Ophthalmol. 2018 02 01; 136(2):209-210.

Chemical Burns of the Eye: The Role of Retinal Injury and New Therapeutic Possibilities. Cornea. 2018 Feb; 37(2):248-251.